KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Bio-Rad Laboratories (BIO) Accumulated Depreciation & Amortization (2016 - 2025)

Bio-Rad Laboratories has reported Accumulated Depreciation & Amortization over the past 17 years, most recently at $165.4 million for Q4 2025.

  • Quarterly Accumulated Depreciation & Amortization rose 9.1% to $165.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $165.4 million through Dec 2025, up 9.1% year-over-year, with the annual reading at $165.4 million for FY2025, 9.1% up from the prior year.
  • Accumulated Depreciation & Amortization was $165.4 million for Q4 2025 at Bio-Rad Laboratories, up from $151.6 million in the prior quarter.
  • Over five years, Accumulated Depreciation & Amortization peaked at $1.1 billion in Q2 2023 and troughed at $137.3 million in Q4 2022.
  • The 5-year median for Accumulated Depreciation & Amortization is $971.9 million (2021), against an average of $700.2 million.
  • The largest YoY upside for Accumulated Depreciation & Amortization was 2690.39% in 2021 against a maximum downside of 0.72% in 2021.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $137.6 million in 2021, then decreased by 0.22% to $137.3 million in 2022, then increased by 6.26% to $145.9 million in 2023, then increased by 3.91% to $151.6 million in 2024, then increased by 9.1% to $165.4 million in 2025.
  • Per Business Quant, the three most recent readings for BIO's Accumulated Depreciation & Amortization are $165.4 million (Q4 2025), $151.6 million (Q4 2024), and $145.9 million (Q4 2023).